Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)
Close on Nov 17, 2026Market cap $226.53MP/E –Yield –
Arcturus Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Arcturus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$72.73M. For fiscal 2025 it was -$74.27M. The highest annual figure on record is $31.99M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$74.27M | – |
| FY2024 | Dec 31, 2024 | -$59.75M | – |
| FY2023 | Dec 31, 2023 | -$18.10M | -156.6% |
| FY2022 | Dec 31, 2022 | $31.99M | – |
| FY2021 | Dec 31, 2021 | -$135.04M | – |
| FY2020 | Dec 31, 2020 | -$42.86M | – |
| FY2019 | Dec 31, 2019 | -$6.45M | – |
| FY2018 | Dec 31, 2018 | -$20.76M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$284.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.14M | -159.3% |
| Q1 FY2024 | Mar 31, 2024 | -$5.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$629.00K | -100.4% |
| Q3 FY2023 | Sep 30, 2023 | -$32.41M | – |
| Q2 FY2023 | Jun 30, 2023 | $50.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.87M | – |
| Q4 FY2022 | Dec 31, 2022 | $160.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$42.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.49M | -190.9% |
| Q1 FY2020 | Mar 31, 2020 | -$11.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.54M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.84M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.41M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.76M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.80M | – |
See a number that looks wrong?